Acadian Asset Management’s Lipocine LPCN Stock Holding History

Acadian Asset Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$435K	Buy	+170,417	New	+$410K	﹤0.01%	1486
2023 Q3	–	Sell	-83	Closed	–	–	1762
2023 Q2	$0	Sell	83 -623	-88%	-$2.93K	﹤0.01%	1831
2023 Q1	$3K	Sell	706 -4,298	-86%	-$33.2K	﹤0.01%	1702
2022 Q4	$32K	Hold	5,004	–	–	﹤0.01%	1650
2022 Q3	$37K	Hold	5,004	–	–	﹤0.01%	1535
2022 Q2	$68K	Buy	+5,004	New	+$78K	﹤0.01%	1444
2019 Q2	–	Sell	-1,056	Closed	-$41K	–	1946
2019 Q1	$41K	Buy	+1,056	New	+$32.4K	﹤0.01%	1716

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $606M AUM

Acadian Asset Management's LPCN Position: Q2 2026 in Review

Acadian Asset Management opened a new position in Lipocine (LPCN) in Q2 2026: 170,417 shares worth $435K. The stake represents ﹤0.01% of the portfolio and ranks #1486 among its holdings. This is a return to the name: Acadian Asset Management previously reported a position in LPCN as recently as Q2 2023.

Acadian Asset Management first reported a position in LPCN in Q1 2019 and has held it in 7 quarters since. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Acadian Asset Management held 170,417 shares of Lipocine worth $435K as of Q2 2026.
Lipocine was a new Acadian Asset Management position in Q2 2026.
Lipocine made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1486 holding.
Acadian Asset Management first reported a position in Lipocine in Q1 2019 and has held it in 7 quarters since.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.